dBMHCC

dBMHCC compiles curated and predicted hepatocellular carcinoma (HCC)-related phosphorylated biomarkers and associated expression profiles, phosphorylation events, pathways, phosphorylation motifs, protein kinases, and drug interactions to support biomarker discovery and evaluation.

Key Features:

• Extensive Data Repository: Contains 611 HCC-related genes, 234 HCC-associated pathways, 17 phosphorylation motifs linked to 255 protein kinases, 5,955 identified HCC biomarkers, and 1,077 predicted HCC phosphorylated biomarkers (HCCPMs).
• Predictive Platform: Provides a prediction system for identifying new phosphorylated biomarkers and includes an evaluation framework to assess prediction reliability.
• Pathway and Gene Information: Compiles HCC-related pathways and constituent genes as candidate biomarkers for downstream analysis.
• Phosphorylation Evaluation System: Evaluates protein phosphorylation events and their relevance to HCC.

Scientific Applications:

• Biomarker Discovery: Identification and prioritization of phosphorylated biomarkers in HCC, including predicted candidates Methionine adenosyltransferase 2B (MAT2B) and acireductone dioxygenase 1 (ADI1).
• Drug-target Identification: Characterization of drug–target relationships, exemplified by Platelet-derived growth factor receptor alpha (PDGFRA) as a target of Regorafenib.
• Pathway and Mechanism Analysis: Analysis of HCC-associated pathways and constituent genes to investigate mechanisms of HCC progression and therapeutic strategy development.

Methodology:

Prediction of HCC phosphorylated biomarkers and evaluation of protein phosphorylation events using the database's prediction system and phosphorylation evaluation framework.